Overview

A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the Safety, Tolerability, PK/PD and preliminary Efficacy of ICP-022 in Subjects with Systemic Lupus Erythematosus (SLE)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Beijing InnoCare Pharma Tech Co., Ltd.